Peer-influenced content. Sources you trust. No registration required. This is HCN.

Journal of Clinical OncologyFirst Results of a Head-to-Head Trial of Acalabrutinib vs. Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia

It’s a battle of two heavyweights in this trial report from the Journal of Clinical Oncology, sharing the results of acalabrutinib (Calquence) compared to ibrutinib (Imbruvica) in treating chronic lymphocytic leukemia (CLL). Selected events of clinical interest included cardiac events, atrial fibrillation, ventricular tachyarrhythmias, hypertension, bleeding and major bleeding events, infections, and second primary malignancies excluding non-melanoma skin cancers.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form